Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Omniab, Inc. (OABI)
:OABI
Holding OABI?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 30, 2023
|% Change Since: -28.51%
|Next Earnings Date:Nov 15, 2022
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in active programs and new partnerships, along with positive advancements in clinical developments. However, financial challenges persist with a decrease in revenue and sustained net loss, compounded by industry-wide pressures.Company Guidance
During the third quarter 2024 earnings call for OmniAb, Inc., the company reported several key metrics demonstrating robust performance and growth. OmniAb ended the quarter with 86 active partners, having signed three new platform license agreements with 92Bio, Memorial Sloan Kettering Cancer Center, and Queen Mary University of London. The total number of active programs increased to 352, with 39 new program additions and 12 terminations, reflecting a net growth indicative of the industry's interest in their technology. The company reported $4.2 million in total revenue for the quarter, down from $5.5 million year-over-year, primarily due to lower milestone and ion channel service revenues. OmniAb's partners had 33 active clinical programs and approved products by the end of Q3, with over $550 million in potential milestones. The company maintains a strong financial position with $59.4 million in cash and anticipates ending the year with a cash balance between $50 million and $60 million, factoring in the recent ATM issuance.Strong Growth in Active Programs
Active programs increased to 352 net of attrition with 39 new program additions and only 12 terminations in Q3 2024.
New Licensing Agreements
Three new platform license agreements signed with 92Bio, Memorial Sloan Kettering Cancer Center, and Queen Mary University of London.
Increased Post-Discovery Assets
Post-discovery assets grew by 40% over the past two years, reaching a total of 53 by the end of Q3 2024, with potential milestones over $550 million.
Positive Clinical Developments
Partners Genmab, Merck KGaA, and Teva have advanced programs into clinical trials, showing potential best-in-class profiles.
---
OABI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OABI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $4.49 | $4.07 | -9.35% |
| Aug 08, 2024 | $4.29 | $4.24 | -1.17% |
| May 09, 2024 | $4.57 | $4.68 | +2.41% |
| Mar 20, 2024 | $5.42 | $5.14 | -5.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Omniab, Inc. (OABI) report earnings?
Omniab, Inc. (OABI) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Omniab, Inc. (OABI) earnings time?
Omniab, Inc. (OABI) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OABI EPS forecast?
OABI EPS forecast for the fiscal quarter 2024 (Q4) is -0.1.
---